Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Checking in with a prescriber of Novartis' Rybelsus (semaglutide) as a first-line therapy for adults with type 2 diabetes.

Ticker(s): NVO

Who's the expert?

Institution: Optum

Board Certified Endocrinologist in practice in New York; fellowship trained at Rutgers Robert Wood Johnson University Hospital.
Treats over 600 patients with type 2 diabetes.
Specializes in all disorders of the Endocrine system with a special interest in diabetes and thyroid disorders. She also performs ultrasound guided fine needle aspirations of the thyroid.

Interview Goal

This conversation will focus on the type 2 diabetes treatment landscape. We'll speak to an endocrinologist about prescribing patterns for Rybelsus.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.